Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (41)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fattore, L.
Right arrow Articles by Fratta, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fattore, L.
Right arrow Articles by Fratta, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Alcohol and Alcoholism Vol. 37, No. 5, pp. 495-498, 2002
© 2002 Medical Council on Alcohol


PROCEEDINGS OF A SYMPOSIUM ENTITLED: 'GABAB RECEPTORS: A TARGET OF NEW TREATMENTS FOR ALCOHOLISM AND DRUG ABUSE'

BACLOFEN ANTAGONIZES INTRAVENOUS SELF-ADMINISTRATION OF NICOTINE IN MICE AND RATS

Liana Fattore1, Gregorio Cossu, Maria Cristina Martellotta and Walter Fratta*

Department of Neuroscience, University of Cagliari and
1 CNR Centre for Neuropharmacology, Cittadella Universitaria di Monserrato, SS 554, 09042 Monserrato, Cagliari, Italy

Received 1 March 2002; accepted 21 March 2002

ABSTRACT

Aims: {gamma}-Aminobutyric acid (GABA)-ergic transmission plays an important role in modulating reinforcing effects of different drugs of misuse. In particular, stimulation of GABAB receptors negatively influences self-administration of cocaine, heroin, nicotine, alcohol and {gamma}-hydroxybutyric acid. The effect and specificity of the GABAB agonist baclofen on nicotine misuse were studied on two animal models of self-administration. Methods: The effects of RS baclofen and the two isomers R baclofen and S baclofen were studied on the acute nicotine self-administration in drug-naïve mice. The effect of RS baclofen was also studied in rats trained to chronically self-administer nicotine under a continuous reinforcement (FR1) schedule. Results: RS baclofen antagonizes nicotine intravenous self-administration at doses of 1.25–2.5 mg/kg intraperitoneally (i.p.). Furthermore, this effect is sterospecific. R baclofen completely prevented nicotine self-administration at the dose of 0.625 mg/kg i.p., whereas S baclofen was inactive up to the dose of 2.5 mg/kg i.p. In rats trained to self-administer nicotine, pretreatment with RS baclofen at the dose of 2.5 mg/kg i.p. significantly increased the rate of responding for nicotine. This effect was similar to the effect obtained when rats were pretreated with the nicotine central receptor antagonist mecamylamine (1 mg/kg i.p.). Conclusions: These data show that baclofen is able to antagonize nicotine-rewarding effects in mice and rats and suggest its potential clinical utility for the treatment of nicotine misuse.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Neurosci.Home page
S. Pons, L. Fattore, G. Cossu, S. Tolu, E. Porcu, J. M. McIntosh, J. P. Changeux, U. Maskos, and W. Fratta
Crucial Role of {alpha}4 and {alpha}6 Nicotinic Acetylcholine Receptor Subunits from Ventral Tegmental Area in Systemic Nicotine Self-Administration
J. Neurosci., November 19, 2008; 28(47): 12318 - 12327.
[Abstract] [Full Text] [PDF]


Home page
Phil Trans R Soc BHome page
A. Markou
Neurobiology of nicotine dependence
Phil Trans R Soc B, October 12, 2008; 363(1507): 3159 - 3168.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. E. Paterson, S. Vlachou, S. Guery, K. Kaupmann, W. Froestl, and A. Markou
Positive Modulation of GABAB Receptors Decreased Nicotine Self-Administration and Counteracted Nicotine-Induced Enhancement of Brain Reward Function in Rats
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 306 - 314.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
W. H. Berrettini and C. E. Lerman
Pharmacotherapy and Pharmacogenetics of Nicotine Dependence
Am J Psychiatry, August 1, 2005; 162(8): 1441 - 1451.
[Abstract] [Full Text] [PDF]


Home page
Alcohol AlcoholHome page
O. AMEISEN
COMPLETE AND PROLONGED SUPPRESSION OF SYMPTOMS AND CONSEQUENCES OF ALCOHOL-DEPENDENCE USING HIGH-DOSE BACLOFEN: A SELF-CASE REPORT OF A PHYSICIAN
Alcohol Alcohol., March 1, 2005; 40(2): 147 - 150.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Lerman, F. Patterson, and W. Berrettini
Treating Tobacco Dependence: State of the Science and New Directions
J. Clin. Oncol., January 10, 2005; 23(2): 311 - 323.
[Abstract] [Full Text] [PDF]


Home page
Alcohol AlcoholHome page
G. Colombo, S. Serra, G. Brunetti, G. Atzori, M. Pani, G. Vacca, G. Addolorato, W. Froestl, M. A. M. Carai, and G. L. Gessa
THE GABAB RECEPTOR AGONISTS BACLOFEN AND CGP 44532 PREVENT ACQUISITION OF ALCOHOL DRINKING BEHAVIOUR IN ALCOHOL-PREFERRING RATS
Alcohol Alcohol., September 1, 2002; 37(5): 499 - 503.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.